key: cord-0011513-ey6g4ko4
authors: Kreitmann, Louis; Argaud, Laurent; Ovize, Michel; Cour, Martin
title: Cyclosporine A prevents cardiac arrest-induced acute respiratory failure: a post-hoc analysis of the CYRUS trial
date: 2020-04-21
journal: Intensive Care Med
DOI: 10.1007/s00134-020-06043-0
sha: f72b710188e5a63c092f1674c5d8f0cc1dcb63b7
doc_id: 11513
cord_uid: ey6g4ko4

nan

Accumulating evidence suggests that hypoxemic acute respiratory failure (ARF) is independently associated with poor outcomes in patients successfully resuscitated after out-of-hospital cardiac arrest (OHCA) [1] . This finding opens new therapeutic perspectives, targeting lung injury, to improve the prognosis of OHCA patients. Experimentally, Cyclosporine A (CsA) has been shown to prevent systemic inflammation-induced ARF [2, 3] . To investigate the effect of CsA on ARF in the clinical setting, we conducted a post-hoc analysis of the prospective, multicenter, randomized CsA in OHCA resuscitation (CYRUS) trial (ClinicalTrials.gov identifier: NCT01595958).

The CYRUS trial failed to demonstrate a significant decrease in the sequential organ failure assessment (SOFA) score at 24 h after nonshockable OHCA in patients receiving a prehospital single injection of 2.5 mg/ kg CsA [4] . All the 129 patients alive at 24 h included in the intention-to-treat analysis (67 in the CsA group and 62 in the control group) were analyzed in the present post-hoc analysis (without correction for multiple comparison), in which the primary endpoint was the occurrence of ARF at 24 h, as defined by a SOFA respiratory sub-score > 2. The CsA effect was adjusted for history of respiratory disease, respiratory cause of OHCA and for relevant variables with p < 0.1 after univariate analysis.

Patient's and OHCA's characteristics were well matched between the two groups ( Table 1) . At admission, both the median (interquartile) ratio of the arterial partial pressure of oxygen to the fractional inspired oxygen (PaO 2 /FiO 2 ) and the percentage of patients with ARF did not significantly differ between the CsA and the control groups: 211 (133-319) versus 207 (131-318) mmHg and 34.3% versus 32.3%, respectively. At 24 h, ARF was significantly less frequent in the CsA group (29.8%) compared to the control group (54.8%) and median PaO 2 / FiO 2 was 68 mmHg higher in the CsA group (Table 1) . Patients treated with CsA were also less likely to fulfill criteria for acute respiratory distress syndrome (Table 1) . Importantly, CsA was still independently associated with a lower risk for ARF after multivariate analysis (OR 0.33; 95%CI [0.16-0.70], p < 0.01) (Supplementary Table 1 ). This result was confirmed in the per-protocol population of the CYRUS trial (i.e. 61 patients who actually received CsA and 68 patients who did not) by both univariate analysis (ARF in 33% versus 50% of patients, respectively, p < 0.05) and multivariate analysis (OR 0.42; 95%CI [0.20-0.88], p = 0.02).

We report here the first clinical data suggesting that CsA might limit the severity of ARF at 24 h following OHCA. Even though this post-hoc analysis of the CYRUS trial does not provide mechanistic insight, our findings are in line with both experimental and clinical studies reporting potent protective effects of CsA against ischemia/reperfusion (I/R) injury [1, 2, 3, 5] . CsA may indeed limit I/R-induced cellular damages by inhibiting the cyclophilin D-dependent opening of the mitochondrial permeability transition pore and by *Correspondence: martin.cour@chu-lyon.fr preserving oxidative phosphorylation [5] . In acute lung injury models, cytoprotection was also attributed to a decrease in circulating mitochondrial pro-inflammatory and pro-apoptotic factors [2, 3] . Studies are now needed to examine the longer-term effects of CsA on lung injury, which could not be done here due to high early mortality rate.

In conclusion, the present study identified CsA as a potential new therapeutic strategy to prevent cardiac arrest-induced ARF. This finding will need further confirmation.

Data are expressed as median (interquartile range) or number (%) and compared using Wilcoxon, chi-square or Fisher's exact tests, as appropriate OHCA out-of-hospital cardiac arrest, ROSC restoration of spontaneous circulation, SOFA sequential organ failure assessment score, PEEP positive end-expiratory pressure, PaCO 2 arterial partial pressure of carbon dioxide, PaO 2 /FiO 2 ratio of the arterial partial pressure of oxygen to the fractional inspired oxygen *Imputed, if needed, using adjusted pulse saturation of oxygen (SpO 2 ) to FiO 2 ratio (n = 2 patients in the control group) † 

The acute respiratory distress syndrome after out-ofhospital cardiac arrest: Incidence, risk factors, and outcomes

A mechanism study underlying the protective effects of cyclosporine-A on lung ischemia-reperfusion injury

Attenuation of lipopolysaccharide-induced acute lung injury by cyclosporine-A via suppression of mitochondrial DNA

Effect of cyclosporine in nonshockable out-of-hospital cardiac arrest: the CYRUS randomized clinical trial

Inhibition of mitochondrial permeability transition to prevent the post-cardiac arrest syndrome: a pre-clinical study

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.Accepted: 6 April 2020